Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370609 | 1.00 | AKR1B1 (0.37) | AKR1B1LMNAL3MBTL1 | |
| SCHEMBL31757603 | 0.81 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL8857027 | 0.81 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL458624 | 0.81 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL309710 | 0.81 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL28258836 | 0.76 | AKR1B1 (0.39) | AKR1B1LMNAL3MBTL1 | |
| SCHEMBL3749152 | 0.76 | AKR1B1 (0.39) | AKR1B1LMNAL3MBTL1 | |
| SCHEMBL3239490 | 0.74 | AKR1B1 (0.37) | AKR1B1LMNAL3MBTL1 | |
| SCHEMBL680091 | 0.74 | AKR1B1 (0.37) | AKR1B1LMNAL3MBTL1 | |
| SCHEMBL26929232 | 0.74 | AKR1B1 (0.37) | AKR1B1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214791-B2 | Method for preparation of 2′-deoxy-2′, 2′-difluoro-β-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-β-d-glucose as raw material | SHENZHEN HANDE TECHNOLOGY CO., LTD. (CN) | 2007-05-08 | — | — | US | claimed |
| US-20060003963-A1 | Method for preparation of 2'-deoxy-2', 2'-difluoro-beta-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-beta-D-glucose as raw material | HANDE PHARMA LIMITED (CN) | 2006-01-05 | — | — | US | claimed |
| US-7214791-B2 | Method for preparation of 2′-deoxy-2′, 2′-difluoro-β-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-β-d-glucose as raw material | SHENZHEN HANDE TECHNOLOGY CO., LTD. (CN) | 2007-05-08 | — | — | US | disclosed |
| US-20060003963-A1 | Method for preparation of 2'-deoxy-2', 2'-difluoro-beta-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-beta-D-glucose as raw material | HANDE PHARMA LIMITED (CN) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003963-A1 | Method for preparation of 2'-deoxy-2', 2'-difluoro-beta-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-beta-D-glucose as raw material | DCTD, DPYD, RNGTT | AKR1B1 499/4885LMNA 4177/4885L3MBTL1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.